January 2023

Bimekizumabe em pacientes com artrite psoriática ativa e resposta inadequada anterior ou intolerância a inibidores do fator de necrose tumoral: Um estudo de fase 3, randomizado, duplo-cego, controlado com placebo (BE COMPLETE)

Lancet. 2023 doi: 10.1016/S0140-6736(22)02303-0

This study showed rapid and clinically meaningful improvements with bimekizumab treatment in patients experiencing active PsA and showing an inadequate response or intolerance to TNFα inhibitors. Its chief aim was to evaluate the efficacy and safety of bimekizumab in patients with an inadequate response or intolerance to TNFα inhibitors.

Keywords:

Bimekizumabe em pacientes com artrite psoriática, sem tratamento biológico: Um estudo de fase 3, randomizado, duplo-cego, controlado por placebo (BE OPTIMAL)

Lancet. 2023 doi: 10.1016/S0140-6736(22)02302-9

This study showed that bimekizumab treatment resulted in clinically meaningful and consistent improvements across multiple measures in bDMARD-naïve patients with active PsA. It aimed to assess the efficacy and safety of bimekizumab in patients with active PsA who were naive to bDMARDs.

Keywords:

Eventos Adversos de Influenza em Pacientes com Artrite Reumatoide, Retocolite Ulcerativa ou Pacientes com Artrite Psoriásica nos Programas de Desenvolvimento Clínico de Tofacitinib

Rheumatol Ther. 2022. Epub ahead of print doi: 10.1007/s40744-022-00507-z

This post-hoc analysis of 31 clinical trials in ulcerative colitis, rheumatoid arthritis and psoriatic arthritis concludes that combined influenza adverse event incidence rates were highest in ulcerative colitis, while in each indication they were generally similar across tofacitinib, placebo, and comparator groups.

Keywords: